Protein may be treatment target in advanced PCa

Vancouver, British Columbia - Clusterin, a stress-related protein, appears to inhibit apoptosis associated with androgen withdrawal and may therefore be an important therapeutic target in men with advanced prostate cancer, say researchers from the University of British Columbia.

Related Videos

Related Content

Advertisement

November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke

The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke

The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke

Initial results on ADI-270 are anticipated for the first half of 2025.

November 19th 2024

Dean Laganosky, M.D., named Urology Trailblazer for 2024

MidLantic Urology

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.

Related Content

Advertisement

November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke

The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke

The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.

September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff

In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.

November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke

Initial results on ADI-270 are anticipated for the first half of 2025.

November 19th 2024

Dean Laganosky, M.D., named Urology Trailblazer for 2024

MidLantic Urology

This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.